AstraZeneca Pharma India Limited — Board Meeting, 30-05-2025: Outcome of Board Meeting

AstraZeneca has announced a board meeting on which it approved the audited financial results for the quarter and year ended March 31, 2025. Revenue surged 32% to Rs 1716.3 Cr, with core EPS at Rs 46.30 for FY25. Profit before tax hit Rs 253.15 Cr, and profit after tax came in at Rs 115.74 Cr. The company declared a final dividend of Rs 32 per share, totaling Rs 80 Cr. Strategic highlights include multiple new product launches in Oncology, Biopharma, and Rare Diseases, along with key leadership hires to boost growth and operations.